chemotherapy was based on intraoperative tumor description and clinical factors in line with current guidelines. We extrapolated results to TURBT cases performed for fee-for-service Medicare beneficiaries in 2016. Cost estimates were calculated as if all potential doses of MMC were replaced by gemcitabine across a variety of utilization rates (i.e., actual use, all indicated cases (ideal use), and actual plus ideal (increased use)). We used 2016 Medicare average sales price for typical doses of MMC ($1,152.61) and gemcitabine ($64.99). We used recent real-world estimates of 5% of TURBT cases for Medicare beneficiaries receiving intravesical chemotherapy.
INTRODUCTION AND OBJECTIVES: Previous studies in non-
urologic populations have demonstrated readmission to non-index hospitals can result in increased costs of care, and are a source of variation that can be targeted to decrease costs. However, this has not been well studied in urologic surgery populations. Therefore, our objective was to compare the cost of index vs. non-index readmissions following major urologic oncology surgeries.
METHODS: Patients undergoing radical cystectomy (RC), prostatectomy (RP), nephrectomy (RN), and partial nephrectomy (PN) for urologic cancers were identified between 2010-2014 in the Nationwide Readmissions Database. Among patients who experienced readmission within the 90-day post-operative period, the cost of first readmission was compared between readmissions to index vs. nonindex hospitals. Multivariable models controlling for patient, surgery, and hospital-level characteristics were used to determine if non-index readmission was associated with increased readmission costs.
RESULTS: Following major urologic oncology surgeries, 90-day readmission rates were 40.3% (RC, n[9, 964) , 5.8% (RP, n[12, 341), 14.9% (RN, n[11, 543), 14.0% (PN, n[6, 419) , and 17.6% (NU, n[2, 431) . The percentages of readmitted patients with readmission to non-index hospitals were 26.6% (RC), 30.7% (RP), 28.7%(RN), 25.6% (PN), and 30.3% (NU). On multivariable modeling, non-index hospital readmissions were more expensive following RP ($10,826 vs. $9,585, p<0.001), but less expensive following radical cystectomy ($12,275 vs. $14,543, p[0.001) . The cost of index vs. non-index hospital readmissions was comparable following RN, PN, and NU ( Figure) .
CONCLUSIONS: Hospital readmission to non-index hospitals is a source of significant cost variability following RC and RP. Nonindex readmissions were more expensive than index readmissions following RP, but the opposite was true for RC. This suggests a unique approach must be used for each surgery to understand how to improve readmission costs. As there is increased focus on cost containment with the implementation of bundled payment models, there is a need to better understand the factors associated with cost variability based on hospital readmission location following RC and RP. 
INTRODUCTION AND OBJECTIVES:
Patients with kidney stones often need on-going follow-up and imaging surveillance adding to the clinical burden and cost of treatment. This is usually done in face-to-face clinical appointments. However, this can be avoided in suitably counselled patients who can have a telephone-based nurse led follow-up instead. We look at the outcomes of stone patients from our protocol-based virtual stone follow-up clinic.
METHODS: Over a period of 5 years (2014) (2015) (2016) (2017) (2018) , all patients who were high risk of stone recurrence or with small asymptomatic stones were referred to our protocol-based nurse led virtual telephone stone clinic. The high-risk stone patient group included those with solitary kidneys, bilateral stones, those under 25 years of age, recurrent stone disease, uric acid and cystine stones. The follow-up duration and imaging were tailored and included a 6-or 12-months follow-up with either a plain KUB XR (radio-opaque stones) or USS (radio-lucent stone). The calculated followup cost was $23 for nurse led telephone clinics and $68 for face-to-face outpatient consultant reviews.
The patients on the nurse-led pathway knew that a recurrence of symptoms or stone growth/recurrence or their personal preference would prompt a repeat clinic consultation.
RESULTS: A total of 227 patients (39-49 annually) were referred to the virtual stone clinic for follow-up and surveillance of kidney stones with a mean age of 57 (range: 16-94) and a male:female ratio of 5:4. Of these 2 (1%) declined a virtual follow-up and preferred a face-to-face consultation. Over a mean follow-up of 1.1 years (range 6 months e 2 years), 63 (28%) have been discharged, 114 (50%) continue to be in the virtual clinic, 7 (4%) missed their follow-up and 41 (18%) returned to face-to-face clinical consultation due to recurrence of symptoms or stone growth/recurrence. The imaging modality was with plain KUB XR in 79% and USS in 21% with 34 (15%) patients having more than one follow-up. Based on our model, the overall cost of follow-up reduced by a third from $17,750 to $5,920 over the study period.
CONCLUSIONS: Majority of patients were happy for a virtual nurse led telephone clinic follow-up and half of them continue to be followed this way. Based on the clinical needs, this allowed some patients to be either discharged or returned for a face-to-face clinical consultation. This model not only provided a safe follow-up but also allowed to lower the cost by a third which helps to optimise healthcare resources and reduce the overall cost of treatment.
Source of Funding: None

MP29-06 DELAYS IN PRESENTATION TO UROLOGISTS FOR URINARY STONE DISEASE INCREASE UTILIZATION OF HEALTH CARE RESOURCES
David Bayne*, San Francisco, CA; Manint Usawachintachit, Bangkok, Thailand; Manuel Armas-Phan, San Francisco, CA; David Tzou, Tucson, AZ; Scott Wiener, Marshall Stoller, Tom Chi, San Francisco, CA INTRODUCTION AND OBJECTIVES: Greater than 60% of counties in the United States have no urologists; does this impact stone patient management? Are stone clearance rates impacted by delays in getting to see an urologist? Our objective is to investigate the impact of delays to presentation to urology clinics and delays to surgery on need for repeat kidney stone interventions.
METHODS: A retrospective review of the prospectively collected data from Sept 2015 to July 2018 was conducted to investigate the relationship between delay to seeing an urologist and delay to stone surgery. Data on unilateral stone size, patient age, race, gender, education level, BMI, ASA score, procedure type, mean income per zip code, distance from hospital, history of prior stone surgery, and English as a primary language were included. Univariate analysis was performed in R using Fisher's Exact test and Welch Two Sample t-test. Multivariate analysis was performed using logistic regression. Statistical analysis was performed in R version 3.3.3.
RESULTS: 368 patients with complete data available on need for multiple surgical procedures were identified. When evaluating patients with greater than 90 days between onset of symptoms to presentation to clinic, delays greater than 60 days to surgery, and history of prior stone surgery, only delays to clinic significantly predicted for need for multiple surgical procedures on multivariate analysis (p[0.009, OR 2.28). When controlling for all other variables, only unilateral stone burden >2cm (p<0.001, OR 2.83), English as a second language (p[0.025, OR 2.55), and a history of prior stone surgery (p[0.042, OR 0.60) were significantly associated with delayed presentation to urology clinic >90 days on multivariate analysis. CONCLUSIONS: Delays getting to an urologist predict for need for multiple surgical procedures for stone disease. English as a second language and large stone burden predict for delayed presentation to the urologist. There is need to focus efforts on improving access to care for patients who are vulnerable to delayed presentation to the urologist as it may improve quality of care, increase stone clearance rates, and reduce health care costs. Aggregated data was then split into three cohorts based on patient and hospital county: patients a) receiving care in the same county, b) traveling within and c) traveling outside a CA labor market region. Multivariate logistic regression was performed using variables of age, race, gender, payer group, number of surgeries, urologists, and comorbid conditions. ArcMap 10.5 created choropleth and radial flow maps.
RESULTS: 356,829 surgeries were performed for stones in CA from [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] . Patients left their county for 61,679 (17.3%) surgeries, traveling an average of 70 miles (112 km). SWL was associated with a decreased likelihood of travel independent of age, race, gender, and payer group (p < 0.01 for all). URS and PCNL were not associated with travel out of the patient's county. Independent of procedure type, and controlling for the number of urologists, private insurance or Medicare was associated with travel within (p < 0.001; OR 11.4) and out of a region (p[0.008; OR [ 2.67). Non-white race was inversely correlated with travel within (p <0.001; OR 0.07) or out of (p[0.034; OR [ 0.45) a region. Overall, patients tended to travel from areas with few urologists to areas with many urologists and rarely travel great distance ( Figure) .
CONCLUSIONS: Stone patients are significantly more likely to receive SWL locally than PCNL or URS. Non-white patients or those on Medicaid are significantly more likely to receive care locally, if available, when compared to white patients or those with private insurance or Medicare. The predictable pattern of travel observed in our study is relevant to identify patient populations who may not have adequate access to care, the establishment of hospital network satellite facilities, and targeted marketing.
